Dynamic Advisor Solutions LLC Buys 9,155 Shares of Accuray Incorporated (NASDAQ:ARAY)

Dynamic Advisor Solutions LLC increased its stake in shares of Accuray Incorporated (NASDAQ:ARAYFree Report) by 39.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 32,155 shares of the medical equipment provider’s stock after acquiring an additional 9,155 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Accuray were worth $89,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of ARAY. Ameritas Investment Partners Inc. bought a new position in Accuray during the second quarter valued at about $30,000. Royal Bank of Canada grew its position in Accuray by 251.4% during the second quarter. Royal Bank of Canada now owns 8,343 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 5,969 shares during the period. Commonwealth Equity Services LLC bought a new position in Accuray during the third quarter valued at about $35,000. Zebra Capital Management LLC bought a new position in Accuray during the first quarter valued at about $37,000. Finally, Lazard Asset Management LLC bought a new position in Accuray during the second quarter valued at about $40,000. Institutional investors own 64.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on ARAY shares. TheStreet lowered shares of Accuray from a “c-” rating to a “d+” rating in a research report on Wednesday, February 14th. Roth Mkm started coverage on shares of Accuray in a research report on Tuesday, February 13th. They set a “buy” rating and a $9.00 target price for the company. Finally, Roth Capital reiterated a “buy” rating on shares of Accuray in a research report on Tuesday, February 13th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.25.

Check Out Our Latest Analysis on ARAY

Accuray Price Performance

ARAY stock opened at $2.37 on Wednesday. The firm has a 50 day moving average of $2.66 and a 200-day moving average of $2.71. The company has a current ratio of 1.58, a quick ratio of 0.84 and a debt-to-equity ratio of 3.53. Accuray Incorporated has a 12 month low of $2.36 and a 12 month high of $4.30. The firm has a market capitalization of $235.03 million, a P/E ratio of -15.80 and a beta of 1.44.

Accuray (NASDAQ:ARAYGet Free Report) last released its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). Accuray had a negative net margin of 3.25% and a negative return on equity of 28.11%. The firm had revenue of $107.24 million during the quarter, compared to the consensus estimate of $107.11 million. During the same quarter last year, the business posted ($0.02) earnings per share. As a group, sell-side analysts predict that Accuray Incorporated will post -0.07 earnings per share for the current fiscal year.

Insider Activity at Accuray

In related news, CAO Gina Corradetti sold 14,129 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $2.74, for a total value of $38,713.46. Following the sale, the chief accounting officer now directly owns 196,138 shares of the company’s stock, valued at $537,418.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.78% of the stock is currently owned by insiders.

About Accuray

(Free Report)

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

Further Reading

Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAYFree Report).

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.